Showing results (241-250 of 268) with videos related to
Sort By:
Pageof 27
The Malaysian Journal of Pathology|April 29, 2022
Histopathological and virological features of lung, heart and liver percutaneous tissue core biopsy in patients with COVID-19: A clinicopathological case seriesJ M Ramos-Rincon, C Alenda, R García-Sevila, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 20, 2012
Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapyJ Macías, M M Viloria, A Rivero, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 13, 2012
Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS CohortC Manzardo, A Esteve, N Ortega, et al.AIDS Research and Human Retroviruses|April 25, 2000
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapyK Van Vaerenbergh, K Van Laethem, E Van Wijngaerden, et al.The Journal of Infection|June 24, 2008
HIV-1 infected patients older than 50 years. PISCIS cohort studyG Navarro, M M Nogueras, F Segura, et al.Journal of Virus Eradication|June 18, 2021
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure ConsortiumC Rokx, H A B Prins, L Vandekerckhove, et al.Current HIV Research|February 15, 2019
Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR StudyD Podzamczer, N Rozas, P Domingo, et al.Antiviral Therapy|June 22, 2001
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-upA M Vandamme, F Houyez, D Bànhegyi, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 2015
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029M Surdo, C Alteri, M C Puertas, et al.HIV Medicine|January 15, 2014
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavirE Martinez, A Gonzalez-Cordon, E Ferrer, et al.Pageof 27